While the idea that our gut can influence our brain is not new, this is a rapidly growing area of research. Find out more on how gut microbes influence anxiety and stress and why tackling these psychological traits matters for irritable bowel syndrome.

Non-prescription therapeutics for IBS: where are we?

30 Jan 2024

by Andrea Costantino

Alterations in the gut microbiome composition and functions are emerging as a potential target for managing IBS. Discover how microbiota-modifying treatments, including prebiotics, probiotics, antibiotics, and fecal microbiota transplantation, hold promise in alleviating symptoms of this vexing condition.

Celiac disease is a chronic immune-mediated enteropathy that may be unleashed by enteric viral infections. However, new findings in mice identified a commensal protist, Tritrichomonas arnold, that protects against reovirus-induced intolerance to gluten by counteracting virus-induced proinflammatory dendritic cell activation.

Where are we on microbiome-based therapies in disorders of gut-brain interaction?

4 Dec 2023

by Andreu Prados, Rene van den Wijngaard

NeuroGASTRO 2023, the leading meeting in Europe held by ESNM on the latest developments in neurogastroenterology, digestive motility, and disorders of gut-brain interaction, took place from August 31st to September 2nd, 2023. Find out more about the main takeaways from the role of fecal microbiota transplants, microbial consortia and probiotics in disorders of gut-brain interaction picked up by GMFH editors (Part 2).

NeuroGASTRO 2023, the leading meeting in Europe held by ESNM on the latest developments in neurogastroenterology, digestive motility, and disorders of the gut-brain interaction, took place from August 31st to September 2nd, 2023. Find out more what the latest research says about the involvement of the intestinal microbiota, mast cells, eosinophils and gut barrier in disorders of gut-brain interaction and dietary considerations in their management picked up by GMFH editors (Part 1).

Chronic abdominal pain, diarrhea, constipation, and bloating are common gastrointestinal symptoms. While a structural or an organic disease can be suspected because of the symptoms and is often easy to be diagnosed by endoscopy or imaging methods, sometimes gastrointestinal symptoms are not related to any alteration that may be seen through diagnostic techniques, and consequently have been classified under the umbrella of “disorders of gut-brain interaction”.

Dietary fibers, known to regulate intestinal inflammation and gut barrier functions, have been avoided by patients with inflammatory bowel diseases (IBD) to avoid flare-ups. However, recent findings suggest that if fiber type, patient immunological condition, and the fermentative ability of the gut microbiota are taken into account, they could be beneficial and prevent relapses.

The Digestive Disease Week meeting 2023 covered a considerable variety of basic, translational, and clinical aspects of research in gastrointestinal and extraintestinal human health and disease. This post highlights the major takeaways from the Microbiome & Microbial Therapy sessions and unravels how they might impact daily basic research and clinical practice (part 2).

Differences in the gut microbiota in patients with IBD compared to healthy controls suggest that probiotics may be of help. This article takes an in-depth look into the rationale of using probiotics for IBD and summarizes the evidence from recent clinical guidelines for the use of probiotics in Crohn’s disease, ulcerative colitis and pouchitis.

The DDW meeting 2023 covered a huge variety of basic, translational and clinical aspects of research in gastrointestinal and extraintestinal human health and disease. This post highlights the major-takeaways from the Microbiome & Microbial Therapy sessions and unravels how they might impact daily basic research and clinical practice (part 1).

Go to Top